Logo image of TELA

TELA BIO INC (TELA) Stock Fundamental Analysis

NASDAQ:TELA - Nasdaq - US8723811084 - Common Stock - Currency: USD

1.29  -0.04 (-3.01%)

Fundamental Rating

3

TELA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TELA have multiple concerns. TELA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TELA has reported negative net income.
In the past year TELA has reported a negative cash flow from operations.
TELA had negative earnings in each of the past 5 years.
TELA had a negative operating cash flow in each of the past 5 years.
TELA Yearly Net Income VS EBIT VS OCF VS FCFTELA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

TELA has a worse Return On Assets (-56.24%) than 69.31% of its industry peers.
TELA has a Return On Equity of -239.72%. This is in the lower half of the industry: TELA underperforms 77.78% of its industry peers.
Industry RankSector Rank
ROA -56.24%
ROE -239.72%
ROIC N/A
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
TELA Yearly ROA, ROE, ROICTELA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 66.93%, TELA is doing good in the industry, outperforming 71.96% of the companies in the same industry.
TELA's Gross Margin has improved in the last couple of years.
TELA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
TELA Yearly Profit, Operating, Gross MarginsTELA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TELA has been increased compared to 1 year ago.
The number of shares outstanding for TELA has been increased compared to 5 years ago.
Compared to 1 year ago, TELA has an improved debt to assets ratio.
TELA Yearly Shares OutstandingTELA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TELA Yearly Total Debt VS Total AssetsTELA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -6.12, we must say that TELA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.12, TELA is doing worse than 71.96% of the companies in the same industry.
A Debt/Equity ratio of 2.28 is on the high side and indicates that TELA has dependencies on debt financing.
With a Debt to Equity ratio value of 2.28, TELA is not doing good in the industry: 84.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.28
Debt/FCF N/A
Altman-Z -6.12
ROIC/WACCN/A
WACC8.57%
TELA Yearly LT Debt VS Equity VS FCFTELA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

TELA has a Current Ratio of 4.22. This indicates that TELA is financially healthy and has no problem in meeting its short term obligations.
TELA has a better Current ratio (4.22) than 66.14% of its industry peers.
TELA has a Quick Ratio of 3.40. This indicates that TELA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.40, TELA is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 3.4
TELA Yearly Current Assets VS Current LiabilitesTELA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.57% over the past year.
TELA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.79%.
The Revenue has been growing by 35.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%11.55%

3.2 Future

The Earnings Per Share is expected to grow by 25.91% on average over the next years. This is a very strong growth
Based on estimates for the next years, TELA will show a very strong growth in Revenue. The Revenue will grow by 22.52% on average per year.
EPS Next Y47.83%
EPS Next 2Y30.42%
EPS Next 3Y27.74%
EPS Next 5Y25.91%
Revenue Next Year14.91%
Revenue Next 2Y18.73%
Revenue Next 3Y19.68%
Revenue Next 5Y22.52%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TELA Yearly Revenue VS EstimatesTELA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
TELA Yearly EPS VS EstimatesTELA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TELA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TELA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELA Price Earnings VS Forward Price EarningsTELA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELA Per share dataTELA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as TELA's earnings are expected to grow with 27.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.42%
EPS Next 3Y27.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TELA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELA BIO INC

NASDAQ:TELA (5/21/2025, 10:42:08 AM)

1.29

-0.04 (-3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners67.78%
Inst Owner Change-9.26%
Ins Owners7.76%
Ins Owner Change5.21%
Market Cap51.02M
Analysts81.82
Price Target5.92 (358.91%)
Short Float %1.96%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.26%
Min EPS beat(2)-25.31%
Max EPS beat(2)-1.21%
EPS beat(4)0
Avg EPS beat(4)-8.57%
Min EPS beat(4)-25.31%
Max EPS beat(4)-1.21%
EPS beat(8)3
Avg EPS beat(8)3.37%
EPS beat(12)4
Avg EPS beat(12)-0.21%
EPS beat(16)4
Avg EPS beat(16)-3.37%
Revenue beat(2)1
Avg Revenue beat(2)-10.36%
Min Revenue beat(2)-25.31%
Max Revenue beat(2)4.59%
Revenue beat(4)1
Avg Revenue beat(4)-9.17%
Min Revenue beat(4)-25.31%
Max Revenue beat(4)4.59%
Revenue beat(8)2
Avg Revenue beat(8)-5.69%
Revenue beat(12)4
Avg Revenue beat(12)-5.04%
Revenue beat(16)7
Avg Revenue beat(16)-2.46%
PT rev (1m)0%
PT rev (3m)-36.96%
EPS NQ rev (1m)-3.03%
EPS NQ rev (3m)-2.79%
EPS NY rev (1m)-8.88%
EPS NY rev (3m)-10.27%
Revenue NQ rev (1m)-1.52%
Revenue NQ rev (3m)-7.12%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)-8.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 3.1
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS1.8
BVpS0.46
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.24%
ROE -239.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.93%
FCFM N/A
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
F-Score4
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 2.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.61%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 3.4
Altman-Z -6.12
F-Score4
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)110.61%
Cap/Depr(5y)96.68%
Cap/Sales(3y)2.33%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y47.83%
EPS Next 2Y30.42%
EPS Next 3Y27.74%
EPS Next 5Y25.91%
Revenue 1Y (TTM)12.79%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%11.55%
Revenue Next Year14.91%
Revenue Next 2Y18.73%
Revenue Next 3Y19.68%
Revenue Next 5Y22.52%
EBIT growth 1Y12.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.33%
EBIT Next 3Y33.29%
EBIT Next 5Y35.84%
FCF growth 1Y13.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.83%
OCF growth 3YN/A
OCF growth 5YN/A